Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of nebulized CSL787 (human normal immunoglobulin G) in adults with non-cystic fibrosis bronchiectasis
2024-518821-13-00Phase 2Authorised
- Sponsor
- CSL Behring
- Start
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 23
01
Overview
Phase 2, randomised, double-blind trial of CSL787 in bronchiectasis (3 arms), sponsored by CSL Behring. Primary endpoint: Time to first exacerbation. Planned start Sep 2025; status: authorised.
02
Drugs
CSL787
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on 2024-518821-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518821-13-00.